IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Patients with metastatic or recurrent and refractory sarcomas have a dismal prognosis. Therefore, new targeted therapies are urgently needed. This study was designed to evaluate chimeric antigen receptor (CAR) T cells targeting the type I insulin-like growth factor receptor (IGF1R) or tyrosine kinase-like orphan receptor 1 (ROR1) molecules for their therapeutic potential against sarcomas. Here, we report that IGF1R (15/15) and ROR1 (11/15) were highly expressed in sarcoma cell lines including Ewing sarcoma, osteosarcoma, alveolar or embryonal rhabdomyosarcoma, and fibrosarcoma. IGF1R and ROR1 CAR T cells derived from eight healthy donors using the Sleeping Beauty (SB) transposon system were cytotoxic against sarcoma cells and produced high levels of IFN-γ, TNF-α and IL-13 in an antigen-specific manner. IGF1R and ROR1 CAR T cells generated from three sarcoma patients released significant amounts of IFN-γ in response to sarcoma stimulation. The adoptive transfer of IGF1R and ROR1 CAR T cells derived from a sarcoma patient significantly reduced tumor growth in pre-established, systemically disseminated and localized osteosarcoma xenograft models in NSG mice. Infusion of IGF1R and ROR1 CAR T cells also prolonged animal survival in a localized sarcoma model using NOD/scid mice. Our data indicate that both IGF1R and ROR1 can be effectively targeted by SB modified CAR T cells and that such CAR T cells may be useful in the treatment of high risk sarcoma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The preclinical study conducted by Huang et al. demonstrated that IGF1R and ROR1 CAR-T cells exhibited significantly tumor growth inhibition and survival extension on sarcoma [127].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 4×
“Recent Phase I clinical trials with CD19-targeted, 2 generation of chimeric antigen receptor (CAR) T cells containing 4-1BB signaling domain have shown a complete remission (CR) rate of>86% in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [3].”
BackgroundInfluentialChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 3×
“In addition, CD19 CAR T cell therapy alone or in combination with hematopoietic stem cell transplantation also showed promise in adult patients with chronic lymphocytic leukemia (CLL) and ALL [4, 5].”
BackgroundBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 3×
“In addition, CD19 CAR T cell therapy alone or in combination with hematopoietic stem cell transplantation also showed promise in adult patients with chronic lymphocytic leukemia (CLL) and ALL [4, 5].”
BackgroundRobbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632 · cited 1×
“In sarcomas, ACT with NY-ESO-1 TCR has demonstrated objective clinical responses in four of six patients with synovial cell sarcoma [8].”
BackgroundPule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
The insulin and insulin-like growth factor receptor family in neoplasia: an update
Pollak, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3215 · Cited by 1,116 · cited 3×
“Therefore, successful targeting IGF1R has a broad impact on cancer treatment [17, 42, 43].”
BackgroundAhmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Evidence that a Single Peptide–MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response
Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., & Eisen, H. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80483-5 · Cited by 703 · cited 1×
“First, they directly and specifically kill IGF1R cancer cells even at a low level of surface expression as CD8 CTLs are capable of responding to a single antigen molecule [48].”
BackgroundAntibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Cited by
Items 101–110 of 110
Timpanaro, A., Piccand, C., Dzhumashev, D., Anton-Joseph, S., Robbi, A., Moser, J. J., Rössler, J. K., & Bernasconi, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.05.555125
“The corresponding CAR T cells showed effective in vitro RMS cell lysis, but have not been tested in vivo (25).”
BackgroundZhou, W., Zhu, X., & Shi, Y. (2025) · Medical Review · doi:10.1515/mr-2024-0099
Transposable Elements in Cancer
Kõks, S. (2025) · Epigenetics and human health · doi:10.1007/978-3-032-04125-8_10
Ewing Sarcoma: Current Advances in Therapy and Prognostic Assessment
张, 葆. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123544
Timpanaro, A., Piccand, C., Dzhumashev, D., Anton-Joseph, S., Robbi, A., Moser, J. J., Rössler, J. K., & Bernasconi, M. (2024) · Figshare · doi:10.6084/m9.figshare.26635719
Timpanaro, A., Piccand, C., Dzhumashev, D., Anton-Joseph, S., Robbi, A., Moser, J. J., Rössler, J. K., & Bernasconi, M. (2024) · Figshare · doi:10.6084/m9.figshare.26635722
CAR-T cell immunotherapy in rhabdomyosarcoma
Kozani, P. S., Shokoohi, S. D., & Kozani, P. S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07773-3
“…and MAPK pathways, and receptor tyrosine kinase-like orphan receptor 1 (ROR1), an oncofetal Wnt ligand receptor promoting metastasis and survival, represent promising targets due to their tumor-selective overexpression in rhabdomyosarcoma with limited normal tissue distribution [135–137].”
InfluentialCAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond
Wells, J., & Gupta, A. K. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10317-2
“Xin Huang et al. investigated insulin-like growth factor receptor (IGF1R) and tyrosine kinase-like orphan receptor 1 (ROR1) as potential CAR-T targets and determined that both were highly expressed among OS, ES, and RMS cell lines [52].”
Paediatric Therapeutic Development Workshop on rhabdomyosarcoma
Baxter, J. S., Montiel-Equihua, C., Molenaar, J. J., Aye, J. M., Bisogno, G., Blanc, P., Breunis, W. B., Chisholm, J., Crane, J. N., Daems, S., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03483-1
Current therapeutic interventions to target cancer stem cells for metastasis
Arora, P., Bhatia, R., Sharma, S., Sharma, A., Chauhan, S. C., Singh, J., & Sharma, A. K. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03154-4
Metadata
- Authors
- Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., Rader, C., Hamby, C. V., Loeb, D. M., Cairo, M. S., & Zhou, X.
- Affiliations
- New York Medical College (US)
- University of Minnesota (US)
- Johns Hopkins University (US)
- Scripps Research Institute (US)
- Corresponding author
- Zhou, Xianzheng
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-07-14
- Volume
- 10
- Issue
- 7
- Pages
- e0133152
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4501840
- OpenAlex
- W925209273
- Cited by
- 109
- References
- 54
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 10 · 2023: 16 · 2022: 10 · 2021: 11 · 2020: 18 · 2019: 8 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 3
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R21AI092220, AI092220)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Keywords
- chimeric antigen receptor T cells, IGF-1 receptor, ROR1, sarcoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, fibrosarcoma, Sleeping Beauty transposon, adoptive T cell therapy, tumor xenograft models, cytokine production, high-risk sarcoma
- MeSH terms
- Animals, Bone Neoplasms, DNA Transposable Elements, Humans, Interferon-gamma, Receptors, Antigen, T-Cell, Sarcoma, T-Lymphocytes, Mice, SCID, Mice, Inbred NOD, Interferon-alpha, Receptors, Somatomedin, Receptor, IGF Type 1, Interleukin-13, Adoptive Transfer, K562 Cells, Cell Line, Tumor, Mice, Receptor Tyrosine Kinase-like Orphan Receptors, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.